Adjuvant chemotherapy may have no significant survival benefit in older patients with stage II/III gastric cancer: a multicenter retrospective study
Age and adjuvant chemotherapy are independent risk factors for OS and CSS in patients with stage II/III GC; for patients with stage II/III gastric cancer aged ≥ 75 years, shared decision-making should be made taking into account functional status and comorbidities, rather than conventional adjuvant chemotherapy.
Authors
- Qin Yang (ORCID: https://orcid.org/0000-0003-0582-057X)
- Mengxuan Cao (ORCID: https://orcid.org/0000-0003-3805-324X)
- Siwei Pan (ORCID: https://orcid.org/0000-0002-8027-9341)
- Can Hu (ORCID: https://orcid.org/0000-0002-9583-9348)
- Zheng-Zheng Shen
- Zaisheng Ye (ORCID: https://orcid.org/0000-0001-9881-6400)
- Zhiyuan Xu (ORCID: https://orcid.org/0000-0001-9663-8401)
- Ruo‐Lan Zhang
- Enze Li (ORCID: https://orcid.org/0000-0002-8812-8222)
- Yanqiang Zhang (ORCID: https://orcid.org/0000-0002-9118-9800)
- Jingyang He
Institutions
- Chinese Academy of Sciences (CN)
- Zhejiang Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1007/s00432-025-06230-w
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China